Compare Mani, Inc. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROE of 11.30%
2
Company has very low debt and has enough cash to service the debt requirements
3
Positive results in Nov 25
4
With ROE of 9.80%, it has a expensive valuation with a 3.06 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 178,588 Million (Small Cap)
31.00
NA
0.00%
-0.40
10.62%
3.15
Revenue and Profits:
Net Sales:
8,278 Million
(Quarterly Results - Feb 2026)
Net Profit:
2,002 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.31%
0%
6.31%
6 Months
14.63%
0%
14.63%
1 Year
41.62%
0%
41.62%
2 Years
-10.75%
0%
-10.75%
3 Years
-6.02%
0%
-6.02%
4 Years
14.32%
0%
14.32%
5 Years
-34.08%
0%
-34.08%
Mani, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.90%
EBIT Growth (5y)
13.94%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
0.54
Tax Ratio
25.45%
Dividend Payout Ratio
82.74%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
26.20%
ROE (avg)
11.30%
Valuation key factors
Factor
Value
P/E Ratio
31
Industry P/E
Price to Book Value
3.06
EV to EBIT
17.57
EV to EBITDA
13.51
EV to Capital Employed
4.32
EV to Sales
4.86
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
24.61%
ROE (Latest)
9.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Aug 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.02%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Feb'26 - QoQ
Feb'26
Nov'25
Change(%)
Net Sales
8,278.00
7,828.00
5.75%
Operating Profit (PBDIT) excl Other Income
3,448.00
2,862.00
20.48%
Interest
1.00
0.00
Exceptional Items
0.00
16.00
-100.00%
Consolidate Net Profit
2,002.00
1,896.00
5.59%
Operating Profit Margin (Excl OI)
343.40%
288.10%
5.53%
USD in Million.
Net Sales
QoQ Growth in quarter ended Feb 2026 is 5.75% vs 1.82% in Nov 2025
Consolidated Net Profit
QoQ Growth in quarter ended Feb 2026 is 5.59% vs 387.40% in Nov 2025
Annual Results Snapshot (Consolidated) - Aug'25
Aug'25
Aug'24
Change(%)
Net Sales
29,968.00
28,513.00
5.10%
Operating Profit (PBDIT) excl Other Income
10,665.00
10,662.00
0.03%
Interest
3.00
6.00
-50.00%
Exceptional Items
-1,175.00
-70.00
-1,578.57%
Consolidate Net Profit
4,643.00
6,286.00
-26.14%
Operating Profit Margin (Excl OI)
273.40%
294.30%
-2.09%
USD in Million.
Net Sales
YoY Growth in year ended Aug 2025 is 5.10% vs 16.44% in Aug 2024
Consolidated Net Profit
YoY Growth in year ended Aug 2025 is -26.14% vs 5.59% in Aug 2024
About Mani, Inc. 
Mani, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






